Magnesium Prophylaxis for the Prevention of New-Onset Atrial Fibrillation in Critically Ill Patients

Conditions de participation

• Sexe:

  ALL

• Âges admissibles:

  18 and up

Critères de participation

Inclusion Criteria:

1. Age ≥18 years
2. Admitted to a critical care unit with EITHER:

1. Non-invasive ventilation (including high flow nasal canula) or invasive mechanical ventilation with an expected duration \>24 hours AND/OR
2. Vasopressor or ionotropic support for shock of any etiology. Shock is defined by the need for one of the following vasopressors/inotropes:

Dopamine Dobutamine Norepinephrine Epinephrine Ephedirine Milrinone at any dose (if used in conjunction with another agent) Vasopressin (if used in conjunction with another agent)
3. Receiving continuous cardiac monitoring.

Exclusion Criteria:

1. Active atrial fibrillation prior to randomization or pre-existing (permanent or paroxysmal) atrial fibrillation
2. Unlikely to survive \>24 hours or palliative patients
3. Cardiac surgery patients
4. Patients requiring parenteral magnesium therapy (e.g. pre-eclampsia, asthma)
5. Patients receiving dialysis
6. Positive pregnancy test
7. Previously enrolled in this trial
8. Treating physician refuses enrollment
9. Receiving ICU intervention (Non-invasive ventilation including High flow nasal canula, invasive mechanical ventilation or ionotropic support) for \>18h hours